biostudies-literatureUnknown87Teofili L<h4>Background</h4>Red blood cell (RBC) transfusions in preterm neonates are associated with retinopathy of prematurity (ROP).<h4>Methods</h4>BORN is a multicenter randomized trial investigating whether RBC transfusions from cord blood (CB-RBCs) instead of adult donors (A-RBCs) reduce ROP severity (NCT05100212). The study was conducted between December 2021 and November 2024 in 8 hospitals sited in 8 different Italian regions. Extremely low gestational age neonates (ELGANs) were randomized 1:1 to receive A-RBCs (control) or CB-RBCs (intervention) from birth to postmenstrual age (PMA) of 29 + 6 weeks. The main outcome was severe-ROP rate at 40 weeks PMA or discharge.<h4>Findings</h4>By intention-to-treat-analysis, 56 patients per arm were evaluated: 16 in the control arm and 14 in the interEClinicalMedicine103426https://www.ebi.ac.uk/biostudies/studies/S-EPMC12361995biostudies-literatureCord red blood cell transfusions for severe retinopathy in preterm neonates in Italy: a multicenter randomized controlled trial.PMC12361995Molisso ABaldascino AAlbiani RPellegrino Cde Vera d' Aragona RPCampagnoli MFVilla SLocatelli EBoggini TCantone GVTeofili LPrati DVento GSerrao FBeccastrini EPatti MLPasciuto TFabbri MRemaschi GFalcone ADragonetti AGiannantonio CVania BPapacci PGhirardello SAnsaldi GBaroni STrimarchi ADani CPurcaro VLepore DCoscia ABesso FGBergamaschi PRaffaeli GCavallaro GGabbriellini SMondello IMozzetta IValentini CGCresi FOrazi LFranco FGSfalseCord red blood cell transfusions for severe retinopathy in preterm neonates in Italy: a multicenter randomized controlled trial.<h4>Background</h4>Red blood cell (RBC) transfusions in preterm neonates are associated with retinopathy of prematurity (ROP).<h4>Methods</h4>BORN is a multicenter randomized trial investigating whether RBC transfusions from cord blood (CB-RBCs) instead of adult donors (A-RBCs) reduce ROP severity (NCT05100212). The study was conducted between December 2021 and November 2024 in 8 hospitals sited in 8 different Italian regions. Extremely low gestational age neonates (ELGANs) were randomized 1:1 to receive A-RBCs (control) or CB-RBCs (intervention) from birth to postmenstrual age (PMA) of 29 + 6 weeks. The main outcome was severe-ROP rate at 40 weeks PMA or discharge.<h4>Findings</h4>By intention-to-treat-analysis, 56 patients per arm were evaluated: 16 in the control arm and 14 in the inter2025-01-01T00:00:00Z2025 Sep2026-07-15T06:45:17.095Z2026-06-30T03:21:46.622ZS-EPMC123619954083819910.1016/j.eclinm.2025.103426